Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.
Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Mixed Phenotype Acute Leukemia|Myelodysplastic Syndromes
DRUG: ORCA-T
Proportion of Patients Without Severe Transplant-Related Adverse Events at Day +100, The proportion of patients who, at Day +100 have not experienced any severe transplant-related adverse events including non-relapse mortality (NRM), primary graft failure, acute GVHD (grade 2-4), acute GVHD grade 3-4, or opportunistic infections (grade 4-5)., 18 months
The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.